Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
Contamination by microorganisms can lead to the production of proteases that rapidly digest Retatrutide
Previously, administration of GC via oral, rectal, IV and IM routes was prohibited in-competition due to clear evidence of systemic effects however this ban has now been extended to include any in-competition injection of GC (e.g., intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g., intrakeloid), intradermal, and subcutaneous)
Its seven-day half-life enables once-weekly dosing, and it reaches steady state at any given dose in approximately four to five weeks